The era of genomics: Impact on sepsis clinical trial design

Critical Care Medicine

Volumn 30, Issue 5 SUPPL., 2002, Pages

  Cariou, Alain ^a   Chiche, Jean Daniel ^a   Charpentier, Julien ^a   Dhainaut, Jean François ^a   Mira, Jean Paul ^a  

^a Cochin St Vincent Paul Univ Hosp ^*  (France)

Author keywords

Genetics; Pharmacogenomics; Polymorphism; Sepsis; Tumor necrosis factor

Indexed keywords

CONFERENCE PAPER; DNA POLYMORPHISM; EXPERIMENTAL DESIGN; GENOMICS; HUMAN; INTENSIVE CARE; MEDICAL GENETICS; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; SEPSIS;

EID: 0036250922     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200205001-00026     Document Type: Conference Paper

References (79)

1. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd.
2. Complete genome sequence of Salmonella enterica serovar Typhimurium LT2
3. Genome sequence of Yersinia pestis, the causative agent of plague
4. Whole-genome analysis: Annotations and updates
5. Initial sequencing and analysis of the human genome
6. A map of human genome sequence variation containing 1.4 million single nucleotide polymorphisms
7. Epidemiology of sepsis: An update
8. Pharmacogenetics in the practice of laboratory medicine
9. Pharmacogenomics: Unlocking the human genome for better drug therapy
10. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
11. ACCP/SCCM consensus conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
12. The immunogenetics of human infectious diseases
13. Defective LPS signaling in C3H/HeJ and C57BL/10ScCR mice: Mutations in TLR4 gene
14. A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection
15. Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock
16. Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence of the Tlr4 as the Lps gene product
17. Tuberculosis in twins: A re-analysis of the Prophit survey
18. Immunogenetics of susceptibility to leprosy, tuberculosis, and leishmaniasis: An epidemiological perspective
19. Hepatitis B virus markers in Chinese twins
20. Twin studies demonstrate a host cell genetic effect on productive human immunodeficiency virus infection of human monocytes and macrophages in vitro
21. Helicobacter pylori infection: Genetic and environmental influences. A study of twins
22. Genetic and environmental influences on premature death in adult adoptees
23. Innate immunity
24. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target
25. Tumor necrosis factor: Biology and therapeutic inhibitors
26. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute phase proteins during the treatment of severe sepsis in humans
27. Circulating endothelin-1 and tumor necrosis factor-alpha: Early predictors of mortality in patients with septic shock
28. Tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned
29. Infliximab approved for use in the Crohn's disease: A report on the FDA GI Advisory Committee Conference
30. Infliximab and methotrexate in the treatment of rheumatoid arthritis
31. Clinical trials of mediator-directed therapy in sepsis: What have we learned?
32. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
33. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: A randomized, controlled, double-blind, multicenter clinical trial
34. Endotoxin-stimulated human monocyte secretion of interleukin-1, tumor necrosis factor alpha, and prostaglandin E2 shows stable interindividual differences
35. Genetic influence on cytokine production and fatal meningococcal disease
36. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation
37. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome
38. A polymorphism than affects OCT-1 binding to the TNF promoter region is associated with severe malaria
39. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study
40. Tumor necrosis factor gene polymorphism and septic shock in surgical infection
41. A tumor necrosis beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus
42. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patients with severe sepsis
43. Relation of a TNF gene polymorphism to severe sepsis in trauma patients
44. Apolipoprotein E alleles and risk of coronary disease: A meta analysis
45. The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A sub-study of the Scandinavian simvastatin survival study
46. Gene expression profile analysis by DNA microarrays
47. Molecular signatures of sepsis
48. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis
49. Human endothelial cell response to Gram-negative lipopolysaccharide assessed with cDNA microarrays
50. Pharmacogenetics in biological perspective
51. Metabolic effects of pyrimidines derived from fava bean glycosides on human erythrocytes deficient in glucose-6-phosphate dehydrogenase
52. Populations and genetic polymorphisms
53. Pharmacogenomics: Translating functional genomics into rational therapeutics
54. Moderne probleme der humangenetik
55. Pharmacogenetic perspectives gained from twin and family studies
56. Genetical and geographical studies on isoniazid inactivation
57. Ethnic differences in drug metabolism
58. A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: The TUCC trial
59. Advances in pharmacogenetics and pharmacogenomics
60. Pharmacogenetics and adverse drug reactions
61. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
62. Potential role of pharmacogenomics in reducing adverse drug reactions
63. Pharmacogenomics: Translating functional genomics into rational therapeutics
64. Molecular basis of cardiovascular drug metabolism implications for predicting clinically important drug interactions
65. Rhabdomyolysis due to interaction of simvastatin with mibefradil
66. Cytochromes P450 and metabolism of xenobiotics
67. Genetic polymorphisms in drug-metabolizing enzymes and drug targets
68. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
69. Association of polymorphisms in the cytochrome P450 CYP2D6 with warfarin dose requirement and risk of bleeding complications
70. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease
71. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: A prospective study
72. Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease
73. Association between FcγRIIa-R131 allotype and bacteremic pneumococcal pneumonia
74. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate
75. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease
76. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease
77. Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis
78. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease
79. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients